环境、社会和公司治理报告 股票代码:688513.SH | 阳光治理 | | | 创新质造 | 标准领航 | 生态药企 | | 履责于行 | ESG绩效 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 关于本报告 | 管理层致辞 | 走进苑东生物 | | | | | | 附录 | | 打造透明高效的管治体系 | | | 以品质守护生命 | | 苑东生物的国际答卷 | 从绿色工厂到零碳未来 | | 筑牢员工关爱与责任担 | | 当基石 | 与未来展望 | | | | | | | | | 关于本报告 | | 002 | 标准领航 | | | 履责于行 | | | | 苑东生物的国际答卷 | | | | | | 筑牢员工关爱与责任担当基石 | | | | 管理层致辞 | | 003 | 国际化战略 国际化认证 | | 042 042 员工福祉 | 践行多元雇佣 | 074 | 066 | | 043 | | | 国际化实施载体 | | 健康安全 | | 077 | | | 走进苑东生物 | | | | | | | | | | 044 | | | ...

医药生物/化学制药 苑东生物（688513.SH） 麻醉业务持续进阶，创新与出海驱动成长 2025 年 04 月 29 日 投资评级：买入（维持） | 日期 | 2025/4/28 | | --- | --- | | 当前股价(元) | 33.59 | | 一年最高最低(元) | 62.40/28.11 | | 总市值(亿元) | 59.30 | | 流通市值(亿元) | 59.30 | | 总股本(亿股) | 1.77 | | 流通股本(亿股) | 1.77 | | 近 3 个月换手率(%) | 106.41 | 股价走势图 数据来源：聚源 -36% -24% -12% 0% 12% 24% 2024-04 2024-08 2024-12 苑东生物 沪深300 相关研究报告 《业绩表现亮眼，麻醉业务持续进阶 —公司信息更新报告》-2024.10.27 《深耕麻醉镇痛领域，积极拓展海外 市场—公司首次覆盖报告》-2024.9.24 余汝意（分析师） 刘艺（联系人） yuruyi@kysec.cn liuyi1@kysec.cn 证书编号：S0790124070022 麻醉业务持续进阶，创新与出海驱动成长，维持 ...

东吴证券股份有限公司朱国广近期对苑东生物进行研究并发布了研究报告《2024年报及2025年一季报点 评：获批新品陆续放量，国际化与创新驱动增长》，给予苑东生物买入评级。 苑东生物(688513) 投资要点 事件：公司近期发布2024年及2025年一季度财报，2024年实现营业收入13.50亿元(+20.82%，括号内为同 比，下同)，实现归母净利润2.38亿元(+5.15%)，实现扣非归母净利润1.75亿元(+10.90%)，剔除股权激励费 用影响，归母净利润同比+13.47%，扣非归母净利润同比+22.87%。25Q1单季度实现营业收入3.06亿元 (-2.97%)，实现归母净利润0.61亿元(-19.22%)，实现扣非归母净利润0.46亿元(-10.79%)，25Q1利润受股权 激励费用短期承压。 各业务板块快速增长，积极拓展海外市场：分产品来看，2024年公司化学制剂板块营收10.77亿元 (+22.25%)，原料药板块营收1.21亿元(+28.65%)，CMO/CDMO业务营收0.65亿元(+111.59%)，技术服务及 转让营收0.63亿元(-42.81%)。分地区看，国内实现收入13.24亿元(+ ...

证券研究报告·公司点评报告·化学制药 苑东生物（688513） 2024 年报及 2025 年一季报点评：获批新品 陆续放量，国际化与创新驱动增长 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1117 | 1350 | 1593 | 1895 | 2261 | | 同比（%） | (4.56) | 20.82 | 18.02 | 18.98 | 19.31 | | 归母净利润（百万元） | 226.57 | 238.23 | 281.30 | 335.30 | 400.75 | | 同比（%） | (8.09) | 5.15 | 18.08 | 19.20 | 19.52 | | EPS-最新摊薄（元/股） | 1.28 | 1.35 | 1.59 | 1.90 | 2.27 | | P/E（现价&最新摊薄） | 26.62 | 25.32 | 21.44 | 17.99 | 15.05 | [Table_T ...

Core Viewpoint - Since the "14th Five-Year Plan," China's pharmaceutical industry has transitioned from a phase of rapid growth to a new stage of high-quality development, shifting from scale expansion to a coordinated improvement of scale and quality [1] Company Performance - In 2024, the company achieved a revenue of approximately 1.35 billion yuan, a year-on-year increase of 20.82%, and a net profit attributable to shareholders of 238 million yuan, up 5.15% year-on-year [2] - Excluding the impact of stock incentive expenses, the net profit attributable to shareholders and the net profit after deducting non-recurring gains and losses increased by 13.47% and 22.87% respectively [2] - The company's revenue from the formulation segment reached 1.077 billion yuan, a growth of 22.25%, while the raw material drug segment generated 121 million yuan, up 28.65% [2] Product Development - The company submitted 18 new formulation product registration applications in 2024 and obtained approvals for 13 new formulation products, including domestic first generics [3] - The company has a strong iterative capability in high-end generics, which continues to contribute to performance growth [3] - The company has completed the industrialization of six special narcotic products and has 16 products listed in the narcotic analgesic field, with over 20 products under research [3][4] R&D Investment - The company maintains a high R&D investment intensity, with 2024 R&D expenditure of approximately 290 million yuan, a year-on-year increase of 16.88%, accounting for 21.31% of revenue [4] - Since 2021, the proportion of R&D investment to revenue has consistently exceeded 20% [4] Internationalization Strategy - The company has made significant progress in internationalizing its raw materials, with several products receiving international approvals, including FDA and EU certifications [7] - The company has successfully commercialized its first product in the U.S. market, marking a breakthrough from 0 to 1 [7] Digital Transformation - In 2024, the company focused on a "digital intelligence" strategy, enhancing its industrial platform and achieving digital management across the entire drug research and production process [8] - The company has received certifications for data management and intelligent manufacturing capabilities, indicating progress in its digital transformation efforts [8] Future Outlook - In 2025, the company aims to accelerate its transformation from generics to innovation, positioning innovation as the core engine for high-quality development [8]